WO2007014051A3 - Use of amylin and amylin agonists as cardioprotective or myoprotective agents - Google Patents

Use of amylin and amylin agonists as cardioprotective or myoprotective agents Download PDF

Info

Publication number
WO2007014051A3
WO2007014051A3 PCT/US2006/028410 US2006028410W WO2007014051A3 WO 2007014051 A3 WO2007014051 A3 WO 2007014051A3 US 2006028410 W US2006028410 W US 2006028410W WO 2007014051 A3 WO2007014051 A3 WO 2007014051A3
Authority
WO
WIPO (PCT)
Prior art keywords
amylin
cardioprotective
myoprotective
agents
agonists
Prior art date
Application number
PCT/US2006/028410
Other languages
French (fr)
Other versions
WO2007014051A2 (en
Inventor
Andrew A Young
Original Assignee
Amylin Pharmaceuticals Inc
Andrew A Young
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc, Andrew A Young filed Critical Amylin Pharmaceuticals Inc
Priority to EP06788137A priority Critical patent/EP1912666A2/en
Publication of WO2007014051A2 publication Critical patent/WO2007014051A2/en
Publication of WO2007014051A3 publication Critical patent/WO2007014051A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Methods for provided for the use of amylin and amylin agonists as a cardioprotective agent. Compounds of the invention are used to reduce, prevent, or delay the mortality and/or morbidity associated with heart disease. Compounds of the invention are useful for treating or preventing cardiac and/or cardiovascular diseases. Compounds of the invention are useful for increasing or promoting the health of the heart.
PCT/US2006/028410 2005-07-22 2006-07-21 Use of amylin and amylin agonists as cardioprotective or myoprotective agents WO2007014051A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06788137A EP1912666A2 (en) 2005-07-22 2006-07-21 Use of amylin and amylin agonists as cardioprotective or myoprotective agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70148005P 2005-07-22 2005-07-22
US60/701,480 2005-07-22

Publications (2)

Publication Number Publication Date
WO2007014051A2 WO2007014051A2 (en) 2007-02-01
WO2007014051A3 true WO2007014051A3 (en) 2008-01-17

Family

ID=37311966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028410 WO2007014051A2 (en) 2005-07-22 2006-07-21 Use of amylin and amylin agonists as cardioprotective or myoprotective agents

Country Status (2)

Country Link
EP (1) EP1912666A2 (en)
WO (1) WO2007014051A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2190457A1 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of a defensin peptide as a therapeutic agent
US20100204109A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of c-type natriuretic peptide, alone or in combination with neuropeptide af, as a therapeutic agent
US20130143804A1 (en) * 2010-06-07 2013-06-06 Trustees Of The University Of Pennsylvania Islet Amyloid Polypeptide Toxic Oligomer is a Biomarker of Heart or Kidney Failure in Type-2 Diabetes Mellitus
FR2961105B1 (en) * 2010-06-15 2013-02-08 Servier Lab USE OF THE ASSOCIATION OF A SINUSAL IF CURRENT INHIBITOR AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR THE TREATMENT OF CARDIAC INSUFFICIENCY
CN106687474A (en) 2014-09-04 2017-05-17 诺和诺德股份有限公司 Novel amylin and calcitonin receptor agonist
PE20211202A1 (en) 2017-08-24 2021-07-05 Novo Nordisk As COMPOSITIONS OF GLP-1 AND ITS USES
PE20221575A1 (en) 2020-02-18 2022-10-06 Novo Nordisk As PHARMACEUTICAL FORMULATIONS

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
CN1282536A (en) * 2000-08-29 2001-02-07 刘国柱 Formula of nutritive carrot-gingko beverage and its preparing process
CN1338216A (en) * 2000-08-17 2002-03-06 郭立文 Nutritive food for recovery
WO2003057244A2 (en) * 2002-01-08 2003-07-17 Amylin Pharmaceuticals, Inc. Use of amylin agonists to modulate triglycerides
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2006086769A2 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
WO2006105345A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Compositions and methods for the control, prevention, and treatment of obesity and eating disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
CN1338216A (en) * 2000-08-17 2002-03-06 郭立文 Nutritive food for recovery
CN1282536A (en) * 2000-08-29 2001-02-07 刘国柱 Formula of nutritive carrot-gingko beverage and its preparing process
WO2003057244A2 (en) * 2002-01-08 2003-07-17 Amylin Pharmaceuticals, Inc. Use of amylin agonists to modulate triglycerides
WO2005077072A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2006086769A2 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
WO2006105345A2 (en) * 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Compositions and methods for the control, prevention, and treatment of obesity and eating disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CUPARENCU B ET AL: "Effect of calcitonin on experimental arrhythmias", THERAPIE 1975, vol. 30, no. 4, 1975, pages 555 - 563, XP009091896, ISSN: 0040-5957 *
DATABASE WPI Week 200132, Derwent World Patents Index; AN 2001-300860, XP002457780 *
DATABASE WPI Week 200243, Derwent World Patents Index; AN 2002-395405, XP002457779 *
JIAN-FENG Z ET AL: "STABILIZATION OF CARDIAC RHYTHM IN SUBSEQUENTLY FATAL VENTRICULAR TACHYCARDIA AND FIBRILLATION BY CALCITONIN GENE-RELATED PEPTIDE", INTERNATIONAL JOURNAL OF CARDIOLOGY, vol. 34, no. 1, 1992, pages 101 - 103, XP002457777, ISSN: 0167-5273 *
YOUNG ANDREW: "Cardiovascular effects.", ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2005, vol. 52, 2005, pages 239 - 250, XP009091642, ISSN: 1054-3589 *

Also Published As

Publication number Publication date
EP1912666A2 (en) 2008-04-23
WO2007014051A2 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2006015159A3 (en) Potassium channel inhibitors
WO2007014051A3 (en) Use of amylin and amylin agonists as cardioprotective or myoprotective agents
TW200716591A (en) Novel thiophene derivatives
TW200716552A (en) Novel thiophene derivatives
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007050348A3 (en) Potassium channel inhibitors
TW200738670A (en) Novel thiophene derivatives
WO2006073890A3 (en) Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
PL381247A1 (en) Heterocyclical condensed derivative, the medical composition containing it as well as its treatment application
ITRM20050265A1 (en) MODULAR PROSTHESIS REFINED FOR OSTEOSYNTHESIS, IN PARTICULAR FOR THE OSTEOSYNTHESIS OF THE HUMERUS.
WO2006089871A3 (en) Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
WO2004075823A8 (en) Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament
WO2006122046A3 (en) Vascular disease therapies
WO2007086001A3 (en) Novel pyridine derivatives
ZA200802848B (en) Potassium channel inhibitors
CL2008000594A1 (en) USE OF COMPOUNDS DERIVED FROM HETEROCICLES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND OTHER ACTIVE AGENTS; AND ITS USE TO TREAT DIABETES, CORONARY ARTERIAL DISEASE BETWEEN OTHER DISEASES.
EA200701845A1 (en) ROFLUMILAST FOR TREATMENT OF DIABETES MELLITUS
WO2004032852A3 (en) Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2005030129A3 (en) Quinoline potassium channel inhibitors
BRPI0622419A2 (en) pesticidal and / or herbicidal compositions and methods of using them.
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2006019978A3 (en) Compositions and methods for diagnosis and treatment of epilepsy
WO2006014877A3 (en) Potassium channel inhibitors
WO2005030792A3 (en) Quinoline potassium channel inhibitors
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006788137

Country of ref document: EP